BioInsights - How choosing the right transfection reagent can drastically bring down costs of AAV manufacturing

How choosing the right transfection reagent can drastically bring down costs of AAV manufacturing

Cell & Gene Therapy Insights 2021; 7(11), 1363

10.18609/cgti.2021.179

Published: 23 November 2021
FastFacts
Maxime Dumont

Watch the video or read the poster to learn:

  • How to choose the right transfection reagent
  • Impact of transfection performance on viral vector manufacturing costs and costs per dose
  • How novel technology can reduce AAV manufacturing costs

Maxime Dumont is a cell and gene therapy product manager at Polyplus-transfection®. With two master’s degrees in biochemistry, project management and marketing of pharmaceutical products, Maxime is managing the CGT transfection reagent portfolio for over 4 years.